Promising Phase 3 Data Could Propel Candel Therapeutics
AI Prediction of Candel Therapeutics, Inc. (CADL)
Candel Therapeutics is poised for potential growth with upcoming clinical and regulatory catalysts that could significantly influence its stock price.
Candel Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing viral immunotherapies for cancer treatment. Its lead assets, aglatimagene besadenovec and linoserpaturev, target various cancers including prostate cancer and NSCLC. Key upcoming catalysts include the presentation of Phase 3 prostate cancer data and initiation of a Phase 3 trial for NSCLC. These events, coupled with a strengthened balance sheet and recent financial maneuvers to secure funding into Q1 2028, position the company in a potentially advantageous market position. Successful outcomes in these trials could lead to significant price movement due to the high unmet medical needs and substantial market sizes of the targeted indications.
CADL Report Information
Prediction Date2026-03-18
Close @ Prediction$5.17
Mkt Cap609m
IPO DateN/a
AI-derived Information
Recent News for CADL
- Jun 16, 4:23 pm — CADL SEC filing points to financing activity (ScanScor Filing Bot)
- Jun 5, 6:23 am — CADL Stock Heads For Best Week In A Month Heres Why Retail Is Bullish (Stocktwits)
- Jun 2, 8:05 am — Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer (GlobeNewswire RSS)
- Jun 1, 4:05 pm — Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire RSS)
- May 15, 4:05 pm — Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting (GlobeNewswire RSS)
- May 14, 8:05 am — Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights (GlobeNewswire RSS)
- May 13, 8:05 am — Candel Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire RSS)
- May 4, 8:05 am — Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting (GlobeNewswire)
- May 1, 4:05 pm — Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
- Apr 29, 8:36 am — Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch (Proactive)
- Apr 29, 8:05 am — Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer (GlobeNewswire)
- Apr 29, 7:51 am — Nasdaq falls back after mixed earnings, Fed holds but signals dissent (Proactive)
Welcome to ScanScor. What you're reading is no ordinary summary -- it's the result of a carefully-crafted interactive session with OpenAI's most advanced models crafted from news, trial details, and financial data. This report attempts to maximize the potential for OpenAI's smartest GPT-based analysis engine, guided by tightly structured prompts to expose the forces behind today's market movers and to predict the future.
Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.
Subscribe
Login
Please login to comment
0 Comments
Oldest